Parexel International Corporation today announced that it had entered into a joint venture arrangement with Synchron Research Services Private Limited, pursuant to which it purchased a majority stake in a newly formed entity called PAREXEL International Synchron Private Limited into which Synchron transferred its clinical trial business operations located in Bangalore.
PR
Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Theradiag Snags CE Mark for Biotherapy Monitoring Analyzer
The i-Track10 can be integrated into laboratory automation systems and features random access analysis and continuous loading capabilities.
Petition Urges FDA, DEA to Classify Tramadol as a Schedule II Controlled Substance
The DEA classified tramadol as a Schedule IV controlled substance in 2014.
FDAnews Drug Daily Bulletin
PAREXEL INTERNATIONAL EXPANDS RELATIONSHIP WITH SYNCHRON RESEARCH IN INDIA
June 20, 2006
